| Literature DB >> 22953146 |
Michael J Gawrysiak1, John P Carvalho, Baxter P Rogers, Christopher R N Nicholas, John H Dougherty, Derek R Hopko.
Abstract
Functional neuroimaging is an innovative but at this stage underutilized method to assess the efficacy of psychotherapy for depression. Functional magnetic resonance imaging (fMRI) was used in this case study to examine changes in brain activity in a depressed breast cancer patient receiving an 8-session Behavioral Activation Treatment for Depression (BATD), based on the work of Hopko and Lejuez (2007). A music listening paradigm was used during fMRI brain scans to assess reward responsiveness at pre- and posttreatment. Following treatment, the patient exhibited attenuated depression and changes in blood oxygenation level dependence (BOLD) response in regions of the prefrontal cortex and the subgenual cingulate cortex. These preliminary findings outline a novel means to assess psychotherapy efficacy and suggest that BATD elicits functional brain changes in areas implicated in the pathophysiology of depression. Further research is necessary to explore neurobiological mechanisms of change in BATD, particularly the potential mediating effects of reward responsiveness and associated brain functioning.Entities:
Year: 2012 PMID: 22953146 PMCID: PMC3420547 DOI: 10.1155/2012/152916
Source DB: PubMed Journal: Case Rep Psychiatry ISSN: 2090-6838
Symptom assessment at pre- and posttreatment.
| Measures | BATD | |
|---|---|---|
| Pre | Post | |
| BDI-II | 24 | 2 |
| EROS | 21 | 27 |
| HRSD | 26 | 0 |
| BIS | 9 | 10 |
| BAS-Drive | 9 | 10 |
| BAS-Fun | 7 | 7 |
| BAS-Reward Response | 7 | 7 |
BATD: behavioral activation treatment for depression; BDI: beck depression inventory; EROS: environmental reward observation scale; HRSD: hamilton rating scale for depression; BIS: behavioral inhibition scale; BAS: behavioral activation scale. All scores listed are raw scores.
Figure 1Cross-correlational analyses (CCA) of EROS and BDI-II from preassessment, through each therapy session, and following completion of BATD. CCA statistics showed that BDI-II and EROS scores were statistically significant at lag 0 (r = −0.92, P = 0.000). BDI-II and EROS points reflect measures completed at preassessment, during each of the 8 therapy sessions, and following BATD completion.
BOLD response between pre- and post-BATD.
| Contrast | Side | MNI | Size |
|
|
| ||
|---|---|---|---|---|---|---|---|---|
| Region |
|
|
| |||||
|
| ||||||||
| Middle frontal gyrus/dlPFC | R | 42 | 17 | 31 | 35 | 0.219 | 0.016* | 4.48 |
| Inferior frontal gyrus/moPFC | L | −27 | 35 | −8 | 38 | 0.178 | 0.013* | 4.09 |
| Inferior frontal gyrus/moPFC | R | 24 | 32 | −20 | 18 | 0.663 | 0.070 | 4.23 |
|
| ||||||||
| Subgenual cingulate | −3 | 35 | −20 | 79 | 0.012** | 0.001* | 4.73 | |
| Inferior frontal gyrus/dlPFC | L | −51 | 38 | 16 | 36 | 0.204 | 0.015* | 4.37 |
| Middle frontal gyrus/moPFC | R | 21 | 32 | −20 | 27 | 0.379 | 0.031* | 4.73 |
|
| ||||||||
| Middle frontal gyrus | L | −36 | 44 | 19 | 46 | 0.102 | 0.007* | 4.32 |
MNI: montreal neurological institute coordinates. Size: the number of voxels within a given activation cluster. T-Value: Peak T-Value activation within that cluster. Cluster-defining threshold was a voxel-level P < 0.005, and P-values reflect cluster-level corrected and cluster-level uncorrected. **P < 0.05 (corrected). *P < 0.05 (uncorrected).
Figure 2T-Maps and plot denoting BOLD response. Response to music, agnostic to valence (preferred and neutral versus silence), changed after treatment in the subgenual cingulate (−3 35 −20). BOLD response was deactivated for music conditions, relative silence, before treatment. At posttreatment, this region showed little distinction between music and silence, evidencing an overall reduction in activity. Neurological convention (right on right) is used, and coordinates are in Montreal Neurological Institute space. Statistical map thresholded at P < 0.005. Bar plots show the BOLD responses in the marked regions, and red bars are 90% confidence intervals.